抗糖尿病代謝効果を媒介するアディポネクチン受容体のクローン化
Toshimasa Yamauchi1, Junji Kamon, Yusuke Ito
1Department of Internal Medicine, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655, Japan.
Nature
|June 13, 2003
まとめ
研究者らは,アディポネクチンの血糖値低下およびインスリン感受性の作用を媒介するために重要な2つの新しいアディポネクチン受容体,AdipoR1とAdipoR2を特定しました. これらの受容体は,糖尿病のような代謝障害を理解し,潜在的に治療するための鍵です.
科学分野:
- エンドクリノロジー エンドクリノロジー
- 分子生物学は分子生物学である.
- メタボリック研究
背景:
- アディポネクチンは,抗糖尿病および抗アテロゲン性を持つアディポキンです.
- アディポネクチンの濃度の低下は,肥満,インスリン抵抗性,および2型糖尿病と関連しています.
- アディポネクチンの投与は,臨床前モデルのインスリン感受性およびグルコース代謝を改善します.
研究 の 目的:
- アディポネクチン受容体をコードする補完的なDNAを識別し,クローン化します.
- これらの新しい受容体の表現パターンと機能的役割を特徴付ける.
- アディポネクチンの代謝作用の基礎となる分子機構を解明する.
主な方法:
- 表現クローニングは,アディポネクチン受容体を特定するために使用されました.
- AdipoR1とAdipoR2をコードする補完的なDNAがクローンされた.
- 小さな干渉RNAは,受容体発現を抑制し,機能的結果を評価するために使用されました.
主要な成果:
- 2つのアディポネクチン受容体であるAdipoR1とAdipoR2がクローン化され,成功しました.
- AdipoR1は主に骨格筋で発現し,AdipoR2は主に肝臓で発現する.
- これらの受容体は,AMPキナーゼとPPAR-α活性化,脂肪酸酸化,およびグルコース吸収に対するアディポネクチンの効果を媒介する.
結論:
- AdipoR1とAdipoR2は,アディポネクチンの主要な受容体である.
- これらの受容体は,アディポネクチンのインスリン感受性およびグルコース低下作用に不可欠です.
- これらの受容体の特定は,代謝疾患における治療介入の新たな道を開く.
さらに関連する動画
関連する概念動画
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:30Spare Receptors
Some receptors remain unoccupied even when an agonist produces a maximal response. Such empty ones are called spare receptors. In presence of spare receptors the maximum effect of an agonist drug is achieved with fewer than 100% of the receptors being occupied. To determine the presence of spare receptors, scientists often compare the concentration of the drug needed to produce 50% of the maximum effect (EC50) with the concentration of the drug needed to occupy 50% of the receptors (Kd). If the...
01:31Adrenergic Receptors: ɑ Subtype
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
01:26Adrenergic Receptors: β Subtype
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
01:28Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...